Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HRS-2261 in healthy subjects
NCT05274516Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-2261 in chronic cough (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Mar 2022; status: completed.
02
Drugs
HRS-2261
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05274516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274516.